Key result
Lisinopril plus indapamide fixed-dose combination provides effective, metabolically neutral initial hypertension control.
Why the study?
Does a fixed-dose combination of lisinopril and indapamide improve blood pressure control and adherence in patients with hypertension?
Does a fixed-dose combination of lisinopril and indapamide improve blood pressure control and adherence in patients with hypertension?
A fixed-dose combination of lisinopril and indapamide offers an effective, metabolically neutral initial treatment option for hypertension, improving patient adherence.
The article presents current data on the choice of antihypertensives from the standpoint of patient-centered medicine. The advantages of combined initial therapy includes high medical adherence, achievement of target blood pressure, and organ protection. Data on the effectiveness of a fixed-dose combination of an angiotensin-converting enzyme inhibitor and a thiazide-like diuretic, in particular, the most commonly used angiotensin-converting enzyme inhibitor lisinopril and long-acting indapamide, are presented. This combination is not only highly effective, but also metabolically neutral, which allows it to be used in patients with obesity, diabetes, and liver diseases. Data are presented on the new favorable effects of lisinopril and indapamide, in particular, on the effect of indapamide on the intestinal microbiota. The potential advantages of this combination as an initial therapy for hypertension in Russian patients are described.
No takes yet. Share an insight, caveat, or question.
Подзолков et al. (2023) conducted a review in Hypertension. Fixed-dose combination of lisinopril and indapamide was evaluated. A fixed-dose combination of lisinopril and long-acting indapamide is highly effective and metabolically neutral as an initial therapy for hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: